Fortunato J E, D'Agostino R B, Lively M O
Section of Pediatric Gastroenterology, Hepatology and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Department of Biostatistical Sciences, Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Neurogastroenterol Motil. 2017 Feb;29(2). doi: 10.1111/nmo.12936. Epub 2016 Sep 7.
Pepsin in saliva is a proposed biomarker for oropharyngeal reflux. Pepsin may be prevalent in saliva from subjects with gastro-esophageal reflux and may correlate with proximal reflux by intraluminal impedance/pH monitoring (MII/pH).
Patients (3 days to 17.6 years, n=90) undergoing 24-hour MII/pH monitoring and asymptomatic controls (2 months to 13.7 years, n=43) were included. Salivary pepsin was determined using a pepsin enzyme-linked immunosorbent assay. Eight saliva samples were collected from patients undergoing 24-hr MII/pH: (i) before catheter placement, (ii) before and 30 minutes after each of three meals, and (iii) upon awakening. One sample was collected from each control.
In MII/pH subjects, 85.6% (77/90) had at least one pepsin-positive sample compared with 9.3% (4/43) in controls. The range of pepsin observed in individual subjects varied widely over 24 hours. The average pepsin concentration in all samples obtained within 2 hours following the most recent reflux event was 30.7±135 ng/mL, decreasing to 16.5±39.1 ng/mL in samples collected more than 2 hours later. The frequency of pepsin-positive samples correlated significantly with symptom index (r =0.332, P=.0014), proximal (r =0.340, P=.0010), and distal (r =0.272, P=.0095) MII events.
CONCLUSIONS & INFERENCES: Concentration of salivary pepsin may not be an accurate measure of severity of reflux because of the wide range observed in individuals over 24 hours. Saliva samples must be obtained soon after a reflux event. Defining a regimen for optimal saliva collection may help to achieve the goal of using salivary pepsin as a biomarker for oropharyngeal reflux.
NCT01091805.
唾液中的胃蛋白酶是一种用于诊断口咽反流的潜在生物标志物。胃蛋白酶可能在胃食管反流患者的唾液中普遍存在,并且可能与腔内阻抗/ pH监测(MII / pH)显示的近端反流相关。
纳入接受24小时MII / pH监测的患者(3天至17.6岁,n = 90)和无症状对照者(2个月至13.7岁,n = 43)。使用胃蛋白酶酶联免疫吸附测定法测定唾液胃蛋白酶。从接受24小时MII / pH监测的患者中收集8份唾液样本:(i)放置导管前,(ii)三餐前及每餐30分钟后,以及(iii)醒来时。从每个对照者中收集1份样本。
在MII / pH监测的受试者中,85.6%(77/90)至少有1份胃蛋白酶阳性样本,而对照组为9.3%(4/43)。个体受试者在24小时内观察到的胃蛋白酶范围差异很大。在最近一次反流事件后2小时内获得的所有样本中,胃蛋白酶平均浓度为30.7±135 ng/mL,在2小时后采集的样本中降至16.5±39.1 ng/mL。胃蛋白酶阳性样本的频率与症状指数(r = 0.332,P = 0.0014)、近端(r = 0.340,P = 0.0010)和远端(r = 0.272,P = 0.0095)MII事件显著相关。
由于个体在24小时内观察到的范围广泛,唾液胃蛋白酶浓度可能不是反流严重程度的准确指标。必须在反流事件后不久采集唾液样本。确定最佳唾液采集方案可能有助于实现将唾液胃蛋白酶用作口咽反流生物标志物的目标。
NCT01091805。